3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Penile Neoplasms
1
Non-Small Cell Lung Cancer With HER2- Mutations
1
Melanoma
1
Male Urogenital Diseases
1
Lung Neoplasms
1
First-line Advanced NSCLC Patients
1
Esophageal Squamous Cell Carcinoma
1
Breast Neoplasms
1
Interventions
pembrolizumab
5
fludarabine
2
enfortumab vedotin
2
darolutamide
2
atezolizumab
2
aldesleukin
2
Riluzole
2
Nivolumab
2
Mitomycin
2
Fecal Microbiota Transplantation
2
Cyclophosphamide
2
vedolizumab
1
relatlimab
1
prednylidene
1
olaparib
1
lenvatinib
1
deltacortene
1
cabozantinib
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Tadalafil
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Rivaroxaban
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Pregnancy Tests
1
Prednisone
1
Practice Guidelines as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Urogenital Neoplasms
×
CP protocol
×
Clear all
NCT06353906
2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2
Recruiting
27 enrolled